Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
Applied DNA Sciences, Inc. (APDN) delivers innovative synthetic DNA solutions for therapeutic development, molecular diagnostics, and supply chain security. This news hub provides investors and industry professionals with centralized access to official corporate announcements and verified updates.
Track critical developments across the company's core operations, including advancements in PCR-based DNA production, diagnostic testing services, and anti-counterfeiting technologies. Our curated feed features earnings reports, strategic partnerships, product launches, and regulatory milestones that impact APDN's market position.
Key focus areas include updates on the Linea DNA platform for mRNA therapeutics, CertainT forensic authentication solutions, and clinical testing services. Users benefit from timestamped press releases organized chronologically while maintaining factual accuracy and regulatory compliance.
Bookmark this page for direct access to Applied DNA Sciences' latest financial disclosures, technology patents, and supply chain security initiatives. Check regularly for updates on nucleic acid manufacturing innovations and DNA-based brand protection programs shaping the biotechnology sector.
Applied DNA Sciences, Inc. and the Institute of Hematology and Blood Transfusion are collaborating on a non-viral manufacturing workflow for CAR T-cell therapy. The study aims to reduce costs and improve production efficiency using Linea DNA technology. The abstract will be presented at the European Hematology Association 2024 Congress.
Applied DNA announced its second-quarter fiscal year 2024 financial results, reporting a decline in total revenues to $930 thousand due to the conclusion of a testing contract. Gross profit decreased to $296 thousand, with a decline in the gross profit percentage. Operating expenses decreased to $3.9 million. The loss from operations was $3.6 million, and Adjusted EBITDA was a negative $3.3 million. Cash and cash equivalents stood at $3.1 million. The company underwent a one-for-twenty reverse stock split and regained compliance with the Nasdaq minimum bid price requirement.
Applied DNA Sciences, Inc. (NASDAQ:APDN) has regained compliance with the minimum bid price requirement set by the Nasdaq Stock Market, ensuring that the company's ordinary shares closed at or above $1.00 for a minimum of 10 consecutive business days, as confirmed in a recent notification letter. This achievement signifies a positive development for the company and its shareholders.
FAQ
What is the current stock price of Applied Dna Scie (APDN)?
What is the market cap of Applied Dna Scie (APDN)?
